- Farmakologická léčba obezity a KV riziko2021 | First Faculty of Medicine
- Combined hypolipidemic treatment in patients with high cardiovascular (CV) risk +12009 | Faculty of Medicine in Hradec Králové
- Combined hypolipidemic treatment in patients with high cardiovascular (CV) risk2009 | First Faculty of Medicine
- The conference Tobacco and Health centered at cardiovascular risks2015 | First Faculty of Medicine
- Časování intervence KV rizika jako rozhodující faktor úspěchu2020 | First Faculty of Medicine
- Combined hypolipidemic treatment in jpatients with high cardiovascular (CV) risk +12008 | Faculty of Medicine in Hradec Králové
- Možnosti ovlivnění KV rizika u mladých nemocných s prediabetem a diabetem2017 | Second Faculty of Medicine
- Combined hypolipidemic treatment in jpatients with high cardiovascular (CV) risk2008 | First Faculty of Medicine
- Dapagliflozin - new antidiabetic with a triple beneficial effect on CV risk factors2015 | First Faculty of Medicine
- Použití omega-3 MK v léčbě dyslipidémií a ovlivnění KV rizika: update pro rok 20192019 | First Faculty of Medicine
- Léčebně preventivní péče u nemocných se zvýšeným KV rizikem - projekt Atlet. Konečné výsledky sledováníPublication without faculty affiliation
- Fixed-dose combination of rosuvastatin and ezetimibe2020 | First Faculty of Medicine
- Simultánní intervence více rizikových faktorů - cesta k účinnému snížení kardiovaskulárního rizika2019 | First Faculty of Medicine
- Plant sterols and stanols: not yet own recommendations for diet enrichment targeted reduction of LDL - cholesterol and cardiovascular risk2015 | First Faculty of Medicine
- Hypertenze a zvýšená srdeční frekvence2023 | First Faculty of Medicine
- Low HDL-cholesterol: How it actually is?2021 | First Faculty of Medicine
- Early and comprehensive cardiovascular prevention in a general practitioner's office. Dyslipidemia and hypertension: The two most common risk factors and the possibility of their EARLY control2020 | Second Faculty of Medicine
- Dyslipidemia and hypertension: The two most common risk factors and the possibility of their early contro2020 | Second Faculty of Medicine
- Notes on the new "Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk"2019 | First Faculty of Medicine
- Poznámky k novému "Doporučení pro léčbu dyslipidemií: ovlivnění lipidů ke snížení kardiovaskulárního rizika"2019 | First Faculty of Medicine
- Dapagliflozin snížil riziko hospitalizace pro srdeční selhání a zpomalil progresi renálního onemocnění u diabetiků 2. typu s KV onemocněním nebo vysokým KV rizikem2019 | Faculty of Medicine in Hradec Králové
- Familial dysbetalipoproteinemia: known unknown2022 | First Faculty of Medicine
- Optimální hodnota srdeční frekvence dle nových doporučení?2023 | First Faculty of Medicine
- High prevalence of cadriovascular risk factors and inadequiate control of LDL cholesterol levels in the population of 40-year old men and 50-year old women in the Czech Republic2016 | First Faculty of Medicine
- Zahajování farmakologické léčby a cílové hodnoty krevního tlaku podle nových doporučení Evropské společnosti pro hypertenzi (ESH): stručný komentář2023 | First Faculty of Medicine
- High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome2008 | Central Library of Charles University
- High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents2020 | First Faculty of Medicine